Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2016

View Archived Issues

Sun Biopharma reports progress on phase I trial of SBP-101

CASI Pharmaceuticals' phase II trial of ENMD-2076 meets stage I endpoint

Boehringer Ingelheim Pharma patents aldosterone synthase inhibitors

Anthera Pharmaceuticals says phase III SOLUTION trial will continue

Genentech and Constellation Pharmaceuticals disclose TAF1 inhibitors

Genentech and Constellation Pharmaceuticals present KDM1A inhibitors

Neurocrine Biosciences describes antiepileptic agents

Cancer Research UK launches phase I/II trial to evaluate guadecitabine in resistant bladder cancer

Janssen Research & Development gains FDA breakthrough designation for esketamine

NSAID class may be repurposed to treat Alzheimer's disease

Phase III AFFINITY trial of custirsen does not meet the primary endpoint

Vyriad signs license collaboration with Imanis Life Sciences

Xycrobe Therapeutics enters research agreement with Johnson & Johnson

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Trek Therapeutics in-licenses rights to Medivir's MIV-802

Evgen receives CTA in U.K. for phase II breast cancer trial of SFX-01

Thalidomide reduces VEGF levels in trial in patients with POEMS syndrome

Eiger initiates phase II trial of pegylated interferon lambda for chronic HDV infection

Oncoceutics Pharmaceuticals wins FDA orphan grant for phase II trial of ONC-201

Japan Tobacco seeks Japanese approval for emtricitabine/tenofovir alafenamide

Study adds to complexity of nasal flu vaccine picture

Pilot study explores use of high-dose thyroid hormone to promote remyelination in MS

Phase II trial explores use of abituzumab in systemic sclerosis-associated interstitial lung disease

Karus Therapeutics initiates phase I trial of KA-2237 in B-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...